Sorafenib-induced liver failure

American Journal of Gastroenterology

Volumn 103, Issue 8, 2008, Pages 2162-2163

  Schramm, Christoph ^a   Schuch, Gunter ^a   Lohse, Ansgar W ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; PREDNISOLONE; SORAFENIB;

ADVANCED CANCER; AGED; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CASE REPORT; CAUSE OF DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLICULAR CARCINOMA; HEPATITIS; HUMAN; HUMAN TISSUE; LETTER; LIVER FAILURE; LIVER NECROSIS; PRIORITY JOURNAL; STOMACH PERFORATION; STOMATITIS; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; FEMALE; HUMANS; LIVER FAILURE; PYRIDINES; THYROID NEOPLASMS;

EID: 49349090925     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01982_19.x     Document Type: Letter

References (4)

1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 34.
2. Llovet JM RS, Mazzaferro V, Hilgard P, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007 25 : 962s.
3. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome Eur J Cancer 2006 42 : 548 56.
4. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 24 : 4293 300.